Pfizer signs potential $10.5bn oncology licencing deal with China’s Innovent
The US pharmaceutical giant will pay $650m upfront to support 12 cancer medicine programmes with HKEX-listed Innovent; the collaboration includes co-commercialisation rights in the US and Europe.
May 29, 2026









